Timing of vasopressor initiation and mortality in septic shock: a cohort study

FieldValue
dc.contributor.authorBeck, Vance
dc.contributor.authorChateau, Dan
dc.contributor.authorBryson, Gregory L
dc.contributor.authorPisipati, Amarnath
dc.contributor.authorZanotti, Sergio
dc.contributor.authorParrillo, Joseph E
dc.contributor.authorKumar, Anand
dc.date.accessioned2015-12-18T10:58:14Z
dc.date.available2015-12-18T10:58:14Z
dc.date.issued2014-05-12
dc.identifier.citationCritical Care. 2014 May 12;18(3):R97
dc.identifier.urihttp://dx.doi.org/10.1186/cc13868
dc.identifier.urihttp://hdl.handle.net/10393/33954
dc.description.abstractAbstract Introduction Despite recent advances in the management of septic shock, mortality remains unacceptably high. Earlier initiation of key therapies including appropriate antimicrobials and fluid resuscitation appears to reduce the mortality in this condition. This study examined whether early initiation of vasopressor therapy is associated with improved survival in fluid therapy-refractory septic shock. Methods Utilizing a well-established database, relevant information including duration of time to vasopressor administration following the initial documentation of recurrent/persistent hypotension associated with septic shock was assessed in 8,670 adult patients from 28 ICUs in Canada, the United States of America, and Saudi Arabia. The primary endpoint was survival to hospital discharge. Secondary endpoints were length of ICU and hospital stay as well as duration of ventilator support and vasopressor dependence. Analysis involved multivariate linear and logistic regression analysis. Results In total, 8,640 patients met the definition of septic shock with time of vasopressor/inotropic initiation documented. Of these, 6,514 were suitable for analysis. The overall unadjusted hospital mortality rate was 53%. Independent mortality correlates included liver failure (odds ratio (OR) 3.46, 95% confidence interval (CI), 2.67 to 4.48), metastatic cancer (OR 1.63, CI, 1.32 to 2.01), AIDS (OR 1.91, CI, 1.29 to 2.49), hematologic malignancy (OR 1.88, CI, 1.46 to 2.41), neutropenia (OR 1.78, CI, 1.27 to 2.49) and chronic hypertension (OR 0.62 CI, 0.52 to 0.73). Delay of initiation of appropriate antimicrobial therapy (OR 1.07/hr, CI, 1.06 to 1.08), age (OR 1.03/yr, CI, 1.02 to 1.03), and Acute Physiology and Chronic Health Evaluation (APACHE) II Score (OR 1.11/point, CI, 1.10 to 1.12) were also found to be significant independent correlates of mortality. After adjustment, only a weak correlation between vasopressor delay and hospital mortality was found (adjusted OR 1.02/hr, 95% CI 1.01 to 1.03, P <0.001). This weak effect was entirely driven by the group of patients with the longest delays (>14.1 hours). There was no significant relationship of vasopressor initiation delay to duration of vasopressor therapy (P = 0.313) and only a trend to longer duration of ventilator support (P = 0.055) among survivors. Conclusion Marked delays in initiation of vasopressor/inotropic therapy are associated with a small increase in mortality risk in patients with septic shock.
dc.titleTiming of vasopressor initiation and mortality in septic shock: a cohort study
dc.typeJournal Article
dc.date.updated2015-12-18T10:58:14Z
dc.language.rfc3066en
dc.rights.holderBeck et al.; licensee BioMed Central Ltd.
CollectionLibre accès - Publications // Open Access - Publications

Files